Merck KGaA goes toe to toe with Novartis as FDA green-lights MET inhibitor
Merck KGaA has clinched the big FDA endorsement for its MET inhibitor tepotinib, setting the stage for a market showdown with Novartis.
Tepmetko is the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
